A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of injectable therapies. Because it’s taken orally, it could overcome one of the biggest barriers keeping patients from using current treatments. Researchers say many people still don’t reach safe cholesterol levels—even on statins—highlighting the need for better options.
View the full article